de Barclays BioCryst Pharmaceuticals BCRX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 865 k | Vender |
86,481
-47,116
| -35% | -USD 426 k | ﹤0.01% | 2868 |
|
|
2026
Q1 | USD 1.27 M | Vender |
133,597
-592,770
| -82% | -USD 4.6 M | ﹤0.01% | 2601 |
|
|
2025
Q4 | USD 5.67 M | Vender |
726,367
-55,865
| -7% | -USD 404 k | ﹤0.01% | 2120 |
|
|
2025
Q3 | USD 5.94 M | Vender |
782,232
-21,880
| -3% | -USD 182 k | ﹤0.01% | 2060 |
|
|
2025
Q2 | USD 7.2 M | Comprar |
804,112
+401,512
| +100% | +USD 3.74 M | ﹤0.01% | 1812 |
|
|
2025
Q1 | USD 3.02 M | Vender |
402,600
-61,646
| -13% | -USD 497 k | ﹤0.01% | 2318 |
|
|
2024
Q4 | USD 3.49 M | Vender |
464,246
-12,426
| -3% | -USD 94.3 k | ﹤0.01% | 2459 |
|
|
2024
Q3 | USD 3.62 M | Comprar |
476,672
+250,086
| +110% | +USD 1.9 M | ﹤0.01% | 2355 |
|
|
2024
Q2 | USD 1.4 M | Vender |
226,586
-49,672
| -18% | -USD 274 k | ﹤0.01% | 2385 |
|
|
2024
Q1 | USD 1.4 M | Vender |
276,258
-428,271
| -61% | -USD 2.41 M | ﹤0.01% | 2861 |
|
|
2023
Q4 | USD 4.22 M | Comprar |
704,529
+157,201
| +29% | +USD 911 k | ﹤0.01% | 2255 |
|
|
2023
Q3 | USD 3.88 M | Vender |
547,328
-2,411
| -0.4% | -USD 17.3 k | ﹤0.01% | 1490 |
|
|
2023
Q2 | USD 3.87 M | Vender |
549,739
-153,434
| -22% | -USD 1.23 M | ﹤0.01% | 1494 |
|
|
2023
Q1 | USD 5.86 M | Comprar |
703,173
+218,681
| +45% | +USD 2.11 M | ﹤0.01% | 1435 |
|
|
2022
Q4 | USD 5.56 M | Comprar |
484,492
+72,976
| +18% | +USD 910 k | ﹤0.01% | 1547 |
|
|
2022
Q3 | USD 5.18 M | Comprar |
411,516
+324,633
| +374% | +USD 4.18 M | 0.01% | 1141 |
|
|
2022
Q2 | USD 918 k | Vender |
86,883
-35,444
| -29% | -USD 366 k | ﹤0.01% | 2440 |
|
|
2022
Q1 | USD 1.99 M | Vender |
122,327
-96,205
| -44% | -USD 1.54 M | ﹤0.01% | 1867 |
|
|
2021
Q4 | USD 3.03 M | Comprar |
218,532
+139,616
| +177% | +USD 1.85 M | ﹤0.01% | 2088 |
|
|
2021
Q3 | USD 1.13 M | Vender |
78,916
-3,253
| -4% | -USD 51.3 k | ﹤0.01% | 2714 |
|
|
2021
Q2 | USD 1.3 M | Vender |
82,169
-153,124
| -65% | -USD 2.08 M | ﹤0.01% | 2490 |
|
|
2021
Q1 | USD 2.39 M | Comprar |
235,293
+137,263
| +140% | +USD 1.42 M | ﹤0.01% | 2114 |
|
|
2020
Q4 | USD 730 k | Vender |
98,030
-189,675
| -66% | -USD 978 k | ﹤0.01% | 2981 |
|
|
2020
Q3 | USD 987 k | Vender |
287,705
-86,006
| -23% | -USD 369 k | ﹤0.01% | 2708 |
|
|
2020
Q2 | USD 1.78 M | Vender |
373,711
-775,135
| -67% | -USD 3.1 M | ﹤0.01% | 2230 |
|
|
2020
Q1 | USD 2.3 M | Comprar |
1,148,846
+949,442
| +476% | +USD 2.61 M | ﹤0.01% | 2164 |
|
|
2019
Q4 | USD 688 k | Vender |
199,404
-33,802
| -14% | -USD 85 k | ﹤0.01% | 4014 |
|
|
2019
Q3 | USD 669 k | Vender |
233,206
-127,631
| -35% | -USD 397 k | ﹤0.01% | 4003 |
|
|
2019
Q2 | USD 1.37 M | Comprar |
360,837
+255,012
| +241% | +USD 1.53 M | ﹤0.01% | 3354 |
|
|
2019
Q1 | USD 861 k | Comprar |
105,825
+64,891
| +159% | +USD 556 k | ﹤0.01% | 3569 |
|
|
2018
Q4 | USD 330 k | Vender |
40,934
-4,214
| -9% | -USD 32.8 k | ﹤0.01% | 4196 |
|
|
2018
Q3 | USD 345 k | Comprar |
45,148
+34,050
| +307% | +USD 229 k | ﹤0.01% | 4573 |
|
|
2018
Q2 | USD 64 k | Vender |
11,098
-18,376
| -62% | -USD 101 k | ﹤0.01% | 5509 |
|
|
2018
Q1 | USD 140 k | Comprar |
29,474
+5,801
| +25% | +USD 29.8 k | ﹤0.01% | 5125 |
|
|
2017
Q4 | USD 116 k | Comprar |
23,673
+8,778
| +59% | +USD 42.5 k | ﹤0.01% | 5131 |
|
|
2017
Q3 | USD 78 k | Vender |
14,895
-147,821
| -91% | -USD 757 k | ﹤0.01% | 5095 |
|
|
2017
Q2 | USD 904 k | Comprar |
162,716
+138,029
| +559% | +USD 841 k | ﹤0.01% | 2972 |
|
|
2017
Q1 | USD 208 k | Vender |
24,687
-37,777
| -60% | -USD 263 k | ﹤0.01% | 4278 |
|
|
2016
Q4 | USD 396 k | Comprar |
62,464
+61,050
| +4,318% | +USD 318 k | ﹤0.01% | 3597 |
|
|
2016
Q3 | USD 7 k | Vender |
1,414
-17,159
| -92% | -USD 68.5 k | ﹤0.01% | 5902 |
|
|
2016
Q2 | USD 52 k | Vender |
18,573
-2,095
| -10% | -USD 6.5 k | ﹤0.01% | 4804 |
|
|
2016
Q1 | USD 41 k | Comprar |
20,668
+3,231
| +19% | +USD 14.3 k | ﹤0.01% | 4880 |
|
|
2015
Q4 | USD 175 k | Vender |
17,437
-63,280
| -78% | -USD 629 k | ﹤0.01% | 4011 |
|
|
2015
Q3 | USD 887 k | Comprar |
80,717
+31,633
| +64% | +USD 422 k | ﹤0.01% | 2840 |
|
|
2015
Q2 | USD 686 k | Comprar |
49,084
+45,902
| +1,443% | +USD 522 k | ﹤0.01% | 3210 |
|
|
2015
Q1 | USD 29 k | Vender |
3,182
-3,109
| -49% | -USD 32.2 k | ﹤0.01% | 5623 |
|
|
2014
Q4 | USD 75 k | Vender |
6,291
-4,817
| -43% | -USD 53.2 k | ﹤0.01% | 5404 |
|
|
2014
Q3 | USD 100 k | Vender |
11,108
-4,147
| -27% | -USD 50.8 k | ﹤0.01% | 5326 |
|
|
2014
Q2 | USD 182 k | Comprar |
15,255
+4,915
| +48% | +USD 47.8 k | ﹤0.01% | 4905 |
|
|
2014
Q1 | USD 103 k | Vender |
10,340
-13,668
| -57% | -USD 146 k | ﹤0.01% | 5429 |
|
|
2013
Q4 | USD 168 k | Vender |
24,008
-2,082
| -8% | -USD 13.2 k | ﹤0.01% | 5172 |
|
|
2013
Q3 | USD 183 k | Vender |
26,090
-143,196
| -85% | -USD 726 k | ﹤0.01% | 5131 |
|
|
2013
Q2 | USD 262 k | Comprar |
+169,286
| Nuevas | +USD 292 k | ﹤0.01% | 4920 |
|
Otros fondos que tienen BCRX en su cartera
Posición de Barclays en BCRX: resumen de T2 2026
Barclays redujo su participación en BioCryst Pharmaceuticals (BCRX) en 35% durante T2 2026, al vender acciones por un valor estimado de USD 426 k, y conservó 86,481 acciones valuadas en USD 865 k. La posición representa ﹤0.01% de la cartera y ocupa el puesto #2868.
Barclays reportó por primera vez una posición en BCRX en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. La posición alcanzó su máximo de USD 7.2 M en T2 2025. Al cierre de T2 2026, 319 fondos que sigue Wall St. Rank mantienen una posición en BCRX.
- Al cierre de T2 2026, Barclays tenía 86,481 acciones de BioCryst Pharmaceuticals con un valor de USD 865 k.
- Barclays vendió 47,116 acciones de BioCryst Pharmaceuticals en T2 2026, por un valor estimado de USD 426 k.
- BioCryst Pharmaceuticals representó ﹤0.01% de la cartera de Barclays en T2 2026 y fue su posición número 2868.
- Barclays reportó por primera vez una posición en BioCryst Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- La posición de Barclays en BioCryst Pharmaceuticals alcanzó su máximo de USD 7.2 M en T2 2025.
- Al cierre de T2 2026, 319 fondos que sigue Wall St. Rank tenían BioCryst Pharmaceuticals en cartera.
Según el Informe 13F de Barclays correspondiente a T2 2026, presentado el 14 ago 2026.